US Coronavirus: CDC says passengers should wear masks on all types of public transport


This order will come into force on Monday at 11:59 pm.

It should cover both nose and mouth during waiting, boarding, traveling and disbarking. According to the order the mask requires at least two or more layers of breathable fabric and needs to be secured to the head, ear loops or elastic bands.

The CDC said it reserves the right to enforce the order through criminal penalties, but it “encourages and anticipates widespread voluntary compliance” and expects support from other federal agencies to implement the order is.

After Kovid-19 killed more than 436,000 people in the US, the Biden administration has already called for 100 days of mask use as well as vaccine supplements for each state in hopes of managing the effects 16% increase in allocation. The virus that made January the deadliest month of the pandemic.

Variants may dominate the epidemic going forward

And although vaccines are making their way to the public, health experts say the nation is facing several more months of epidemics, and the proliferation of variants has raised alarm.

More than 400 cases of the first identified coronavirus variant in the UK have been reported across the US, and health experts say new strains such as these may soon be effective.

At least 434 cases of variants were detected in 30 states, the CDC said on Wednesday – the number is more than 100 compared to cases reported just a few days ago.

Officials and experts identified for the first time in the UK version as well as in South Africa have been concerned as they are more easily communicated than the tensions the US has been fighting so far. And as leaders race to get the vaccines delivered to Americans, they say new strains can spread quickly.

Director of National Institute of India, Dr. Anthony Fauci said, “The launch that has been done in relation to the UK (variant) will probably happen by the end of March, in early April, it will actually become more effective in this country.” Allergy and infectious diseases, said during a White House news briefing on Friday.

As the variant Kovid-19 threatens progress, the US weighs Johnson's test results;  Johnson vaccine candidate

“The fact is, when you have a virus that has the ability to transmit more efficiently than the wild type in the community, sooner or later by pure viral dynamics, it will become more effective than the wild type , ”Said Fauci.

On Thursday, the Institute of Health Metrics and Evaluation at the University of Washington is likely to worsen the spread of coronovirus and increase the death toll.

Its model now estimates 594,624 deaths as of May 1, up from the previous forecast of 569,000 deaths by that date.

IHME said that by May 1, a rapid variant spread would bring the number to 620,000. In the worst-case scenario, about 654,000 Americans may have died Kovid-19 by May 1, IHME warned.

Closing the vaccine gap while fighting new strains

According to experts, to control the spread of the virus there is a need to close the gap between the number of vaccine doses available and those that have been administered.

According to the CDC, at least 49,216,500 vaccine doses have been delivered so far and at least 27,884,661 vaccine doses have been delivered.

Experts say they expect existing vaccines to be protective against new strains of the virus, but the nature of South African origins may make them less effective, another hindrance in efforts to bring a sense of normal life to the US Can. .

The coronavirus vaccine makes a long, cold trip to rural America

But officials have also said that they anticipate rapid changes in the production of new boosters or vaccines, thanks to the system already in place.

Biotechnology company Novavax said it is developing boosters to protect against newly emerging strains.

On Thursday, the company announced its vaccine, known as NVX-CoV2373, was found to have an efficacy of 89.3% in a phase 3 clinical trial conducted in the UK and clinical against some variants of the vaccine coronovirus. Appeared to demonstrate efficacy.

In January, Novavax began developing boosters for the new variants, and hopes to select its ideal candidates “in the coming days”.

“The company plans to begin clinical trials of these new vaccines in the second quarter of this year,” Nowax said.

CNN’s Jane Christenson, Rebekah Rees, Lauren Mascarenhas, Michael Nedelman, and Jacqueline Howard contributed to this report.

.

Leave a Reply

Your email address will not be published.